Hidenori Ohe

Requirement of Protocol Biopsy Before and After Complete Cessation of Immunosuppression After Liver Transplantation

Background. Operational tolerance is defined as long-term acceptance of a transplanted organ after complete cessation of immunosuppression (IS), but may not always protect against antigen-dependent changes in graft morphology. Method. IS free patients after living-donor liver transplantation (LDLT) underwent protocol biopsy (tolerance group [Gr-Tol]) and were evaluated for rejection and fibrosis. The degree of fibrosis was compared with those in the patients on maintenance IS group (Gr-IS) and the base line normal liver group (Gr-BS). When bridging fibrosis or progression of fibrosis was observed, IS was reintroduced or increased in Gr-Tol or in the patients in the weaning process. Results. Neither acute nor chronic rejection was observed. The degree of fibrosis, however, was significantly greater in Gr-Tol than those in Gr-IS and Gr-BS. In Gr-Tol, the number of graft infiltrating FOXP3+ cells was significantly increased, the interval between LDLT and biopsy plus the donor age was significantly longer, and recipient age at LDLT was significantly younger, compared with those in Gr-IS. However, none of these three parameters correlated with the degree of fibrosis. In 7 of 11 patients in whom IS was reintroduced or increased, the improvement of fibrosis was observed by the subsequent biopsy. Conclusion. Grafts of operationally tolerant patients after LDLT did not exhibit acute or chronic rejection, but they exhibited fibrosis. It remains elusive whether fibrosis observed in tolerant grafts is antigen dependent. The finding that after the reintroduction or the increase of IS fibrosis was improved supported the possibility that fibrosis in operationally tolerant patients was antigen dependent.

Factors affecting operational tolerance after pediatric living-donor liver transplantation: impact of early post-transplant events and HLA match*

Pediatric recipients of living‐donor liver transplants (LDLT) can often discontinue immunosuppression (IS). We examined factors affecting development of operational tolerance (OT), defined as off IS for >1 year, in this population. A historic cohort analysis was conducted in 134 pediatric primary semi‐allogeneic LDLT. Multivariate logistic regression analysis was used. The frequency of peripheral regulatory T cells (Tregs) was determined at >10 years post‐Tx by FACS analysis. IS was successfully discontinued in 84 tolerant patients (Gr‐tol), but not in 50 intolerant patients (Gr‐intol). The Gr‐intol consisted of 24 patients with rejection (Gr‐rej) and 26 with fibrosis of grafts (Gr‐fib). The absence of early rejection [odds ratio (OR) 2.79, 95% CI 1.11–7.02, P = 0.03], was a positive independent predictor, whereas HLA‐A mismatch (0.18, 0.03–0.91, P = 0.04) was a negative predictor. HLA‐DR mismatches did not affect OT. The Treg frequency was significantly decreased in Gr‐intol (4.9%) compared with Gr‐tol (7.6%) (P = 0.003). There were increased levels of tacrolimus in the first week in Gr‐Tol (P = 0.02). Although HLA‐B mismatch (8.73, 1.09–70.0, P = 0.04) was a positive independent predictor of OT, its clinical significance remains doubtful. In this large cohort of pediatric LDLT recipients, absence of early rejection, HLA‐A match and the later predominance of Tregs are factors associated with OT.

The generation of donor-specific CD4+CD25++CD45RA+ naive regulatory T cells in operationally tolerant patients after pediatric living-donor liver transplantation.

Background. CD4+CD25++CD45RA+ cells (naïve regulatory T cells [naïve-Tregs]) have been identified as a functionally premature form of CD4+CD25+++CD45RA− cells (conventional-Tregs). However, their contribution to transplant tolerance remains to be elucidated. Method. We examined the frequency and the function of conventional and naive-Tregs in the peripheral blood derived from operationally tolerant patients after pediatric living-donor liver transplant (Gr-tol). The data were compared with those of patients who were unable to be weaned off immunosuppression due to rejection (group-intolerance [Gr-intol]), patients in the process of weaning immunosuppression (Gr-weaning) and healthy volunteers (group-healthy volunteers [Gr-vol]). Results. In Gr-tol, the frequency of conventional-Tregs was significantly higher than that in Gr-vol and tended to be higher than that in Gr-intol. The frequency of naive-Tregs was significantly decreased in Gr-intol versus those in Gr-tol, -weaning, and -vol. In mixed lymphocyte reactions, donor-specific hyporesponsiveness of CD4+ cells was observed only in Gr-tol but not in the other groups. Depletion of conventional or naive-Tregs from CD4+ cells demonstrated that the suppressive properties of donor antigen-reactive conventional and naïve-Tregs were upregulated compared with those of third-party antigen-reactive conventional and naïve-Tregs in Gr-tol only. Conclusions. This is the first report providing detailed evidence that donor-specific naïve-Tregs were generated and their suppressive properties were upregulated in the peripheral blood of tolerant patients, whereas their frequency was downregulated in intolerant patients. Therefore, we speculate that not only conventional-Tregs play a role in Tx tolerance but also the role of naïve-Tregs is critical.

Intragraft Vδ1 γδ T cells with a unique T-cell receptor are closely associated with pediatric semiallogeneic liver transplant tolerance.

Background T-cell receptor V&dgr;2 &ggr;&dgr; T cells (V&dgr;2 cells) participate in host defense, whereas V&dgr;1 &ggr;&dgr; T cells (V&dgr;1 cells) may regulate immune responses. V&dgr;1 cells appear to play a role in fetomaternal tolerance and our aim was to examine their role in liver transplant tolerance. Methods To determine whether V&dgr;1 cells increase within accepted grafts after semiallogeneic pediatric liver transplantation, the V&dgr;1/V&dgr;2 ratio was assessed at the transcriptional level and the complementarity-determining region 3 loop of the &dgr; chain of V&dgr;1 cells was sequenced in biopsies from immunosuppression-free (n=6) or almost free (n=3) liver transplant recipients, referred to as group tolerance (Gr-Tol; n=9). The results were compared with biopsies from grafts of recipients on maintenance immunosuppression due to concern of rejection (Gr-IS; n=11). Chronically rejected grafts (Gr-CR; n=6) and normal livers (Gr-NL; n=8) were also examined. Results The V&dgr;1/V&dgr;2 ratio was the highest in Gr-Tol (0.07±0.06) compared with Gr-IS (0.03±0.02; P=0.04), Gr-CR (0.01±0.02; P=0.008), and Gr-NL (0.02±0.04; P=0.01). There was an identical complementarity-determining region 3 sequence (100% homologous) among all recipients in Gr-Tol, which was dominant in six of nine recipients. This sequence was not seen in Gr-IS or Gr-CR, although it was observed in five of six normal livers. Conclusions A unique V&dgr;1-bearing T-cell clone accumulates within accepted human liver grafts. It might be useful as a biomarker of tolerance and the identification of its ligand might aid in the development of a novel strategy for tolerance induction.

Association of anti-human leukocyte antigen and anti-angiotensin II type 1 receptor antibodies with liver allograft fibrosis after immunosuppression withdrawal.

Background Many pediatric patients who receive a living-donor liver transplant undergo withdrawal of immunosuppression (IS). For them, the high incidence of long-term progressive graft fibrosis is of particular concern. Methods We conducted a cross-sectional study including 81 pediatric patients who underwent IS withdrawal after living-donor liver transplant at Kyoto University Hospital and whose serum samples and pathological data could be obtained during the analysis period. We examined the association of donor-specific anti-human leukocyte antigen (HLA) antibody (DSA) and angiotensin II type 1 receptor antibody (anti-AT1R Ab) with posttransplant graft fibrosis. Normalized mean fluorescence intensity (MFI) 5,000 or higher and anti-AT1R Ab concentrations 17 U/mL or higher were both considered high level. The patients were classified into an advanced fibrosis group (AFG) (Ishak score≥3) and a control group (CG) (Ishak score⩽2). Results Only one patient demonstrated DSA class I. Among those who demonstrated DSA class II, more AFG patients than CG patients demonstrated high-level mean fluorescence intensity, although the difference was not significant (64% vs. 39%; P=0.053). The incidence of high-level DSA-DRB1, however, was significantly higher in the AFG than that in the CG (40% vs. 4%; P<0.001), but there was no significant difference in DSA-DQB1 or DSA-DRB345. High-level anti-AT1R Ab was significantly more frequent in the AFG than in the CG (65% vs. 36%; P=0.02). All patients with both high-level DSA-DRB1 and high-level anti-AT1R Ab were found to have advanced fibrosis (P<0.001). Conclusion Anti-AT1R Ab and DSA-DRB1 may be candidates as biomarkers of graft fibrosis; both HLA and non-HLA immunity may be involved in graft fibrosis after IS withdrawal.

Minimal but essential doses of immunosuppression: a more realistic approach to improve long-term outcomes for pediatric living-donor liver transplantation.

REFERENCES 1. World Health Organization. Control of leishmaniasis. Geneva: World Health Organization; 2007. Available at: http://apps.who.int/gb/ ebwha/pdf_files/WHA60/A60_10-en.pdf. Accessed March 25, 2010. 2. Herwalt BL. Leishmaniasis. Lancet 1999; 354: 1191. 3. Antinori S, Cascio A, Parravicini C, et al. Leishmaniasis among organ transplant recipients. Lancet Infect Dis 2008; 8: 191. 4. Badaro R, Jones TC, Carvalho EM, et al. New perspectives on a subclinical form of visceral leishmaniasis. J Infect Dis 1996; 154: 1003. 5. Campos-Varela I, Len O, Castells L, et al. Visceral leishmaniasis among liver transplant recipients: An overview. Liver Transplant 2008; 14: 1816. 6. Murray HW, Berman JD, Davies CR, et al. Advances in leishmaniasis. Lancet 2005; 366: 1561. 7. Horber FF, Lerut JP, Reichen J, et al. Visceral leishmaniasis after orthotopic liver transplantation: Impact of persistent splenomegaly. Transpl Int 1993; 6: 55. 8. Hernandez-Perez J, Yebra-Bango M, JimenezMartinez E, et al. Visceral leishmaniasis (kala-azar) in solid organ transplantation: Report of five cases and review. Clin Infect Dis 1999; 29: 918. 9. Halkic N, Ksontini R, Scholl B, et al. Recurrent cytomegalovirus disease, visceral leishmaniasis, and Legionella pneumonia after liver transplantation: A case report. Can J Anaesth 2004; 51: 84. 10. Tsiodras S, Zafiropoulou R, Giotakis J, et al. Deep sinus aspergillosis in a liver transplant recipient successfully treated with a combination of caspofungin and voriconazole. Transplant Infect Dis 2004; 9: 37. 11. Basset D, Faraut F, Marty P, et al. Visceral leishmaniasis in organ transplant recipients: 11 new cases and review of the literature. Microbes Infect 2005; 7: 1370. 12. Ozcan D, Seckin D, Allahverdiyev AM, et al. Liver transplant recipient with concomitant cutaneous and visceral leishmaniasis. Pediatr Transplant 2007; 11: 228. 13. Murray HW. Treatment of visceral leishmaniasis (Kala-Azar): A decade of progress and future approaches. Int J Infect Dis 2000; 4: 158. 14. Clemente WT, Couto CA, Ribeiro DD, et al. An atypical course of visceral leishmaniasis (Kala-azar) in a liver transplant recipient. Transplantation 2007; 83: 368. 15. Brasil, Ministério da Saúde. Leishmaniose Visceral Grave. Brasília, 2006. Available at: http:// portal.saude.gov.br/portal/arquivos/pdf/ manual_lv_grave_nc.pdf. Accessed March 18, 2010. 16. Brasil, Ministério da Saúde. Leishmaniose visceral. Recomendações clínicas para redução da letalidade. Brasília, 2009. 17. Oliveira CMC, Oliveira MLMB, Andrade SCA, et al. Visceral leishmaniasis in renal transplant recipients: Clinical aspects, diagnostic problems, and response to treatment. Transplant Proc 2008; 40: 755. 18. López-Vélez R, Videla S, Márquez M, et al. Spanish HIV-leishmania study group. Amphotericin B lipid complex versus no treatment in the secondary prophylaxis of visceral leishmaniasis in HIV-infected patients. J Antimicrob Chemother 2004; 53: 540. 19. Fernández-Guerrero ML, Robles P, Rivas P, et al. Visceral leishmaniasis in immunocompromised patients with and without AIDS: A comparison of clinical features and prognosis. Acta Trop 2004; 90: 11.

Value of FOXP3 expression in peripheral blood as rejection marker after miniature swine lung transplantation.

BACKGROUND Outcome for highly immunogenic lung transplantation remains unsatisfactory despite the development of potent immunosuppressants. The poor outcome may be the result of a lack of minimally invasive methods to detect early rejection. There is emerging clinical evidence that, paradoxically, expression of forkhead box P3 (FOXP3, a specific marker for the regulatory T cells) is upregulated within rejecting grafts. METHODS Orthotopic lung transplantation was performed using miniature swine without immunosuppression. Rejection was monitored by chest radiography and open lung biopsy. Expressions levels of FOXP3, perforin, Fas-L and IP-10 mRNA were quantified in the peripheral blood. In addition, rescue immunosuppressive therapy (steroid plus tacrolimus) was administered on post-operative day (POD) 4 or 6. RESULTS Early rejection was detected by open lung biopsy, but misdiagnosed by chest radiography on POD 4. Expression of FOXP3 in the peripheral blood reached its highest value as early as POD 4, followed by a decline. Such an increase of FOXP3 was not observed in recipients given high-dose tacrolimus. Neither perforin, Fas-L or IP-10 in the peripheral blood exhibited significant fluctuations in the early phase of rejection. Rescue immunosuppressive therapy from POD 4, when peak FOXP3 was seen, prolonged graft survival (27.2 days, versus 9.1 days without immunosuppression, p < 0.001), in contrast to POD 6, when rejection was suspected by chest radiography (11.5 days, p = not statistically significant [NS]). CONCLUSIONS In a miniature swine lung transplantation model, the FOXP3 mRNA level in the peripheral blood was upregulated at an early phase of rejection. The clinical implication of this finding remains to be elucidated.

Utility of CD127 combined with FOXP3 for identification of operational tolerance after liver transplantation

Loss of cell surface expression of CD127 on CD4(+)CD25(++) regulatory T-cells (Tregs) may be a useful marker to efficiently isolate Tregs. As FOXP3 was specifically used to identify Tregs, combining these two markers could give better identification for patient with operational tolerance (OT) after liver transplantation. To testify this mixed lymphocyte reaction (MLR), the function of circulating CD4(+)CD25(++)CD127(dim) cells (CD127(dim) cells) was examined in immunosuppression (IS)-free pediatric recipients after liver transplantation (LTx) (group operational tolerance: OT) (Gr-tol n=25) compared to recipients who could not stop IS due to clinically overt rejection (group intolerance) (Gr-intol n=18), recipients who were weaning IS (Gr-weaning n=11) and age-matched healthy volunteers (Gr-vol n=11). In addition, the frequencies of CD127(dim) cells vs CD4(+)CD25(++)CD127(dim)FOXP3(+) (CD127(dim)FOXP3(+)) cells were compared in these four groups by FACS analyses. Our results showed that The proliferation of CD4 cells to donor antigens was reduced compared to third-party antigens only in Gr-tol (P=0.022) but not in other groups (P=NS). Depletion of CD127(dim) cells resulted in a donor antigen-specific abrogation of this MLR hyporesponsiveness in Gr-tol (P<0.001) but not other groups (P=NS). This implied that CD127 efficiently isolated donor antigen-specific Tregs. The frequencies of CD127(dim) cells were significantly lower in Gr-intol (5.2%±1.9%) compared to those in Gr-tol (7.8%±1.8%) (P<0.001) as were the frequencies of CD127(dim) FOXP3(+) cells (Gr-tol: 5.4%±1.7% vs Gr-intol: 2.9%±1.0%, P<0.001). Of interest, there were fewer CD127(dim)FOXP3(+) cells in Gr-intol (2.9%±1%) than in Gr-weaning (5.1%±1.8%) (P=0.002), but no difference in CD127(dim) cells (Gr-intol: 5.2%±1.9% vs Gr-weaning: 6.7%±2.0%) (NS). Thus, combining FOXP3 with CD127 for phenotype analysis demonstrated an unequivocal difference between Gr-intol and Gr-weaning that was not detected by CD127 alone. In conclusion CD127 was a useful surface marker to isolate donor-antigen-specific-Tregs in OT after LTx. The additive effect of its combination with FOXP3 is important in phenotypical Treg analyses of OT patients.

Biomarkers of Operational Tolerance in Liver Transplantation

Operational tolerance (OT), defined as continued function of a transplanted organ in the absence of immunosuppression (IS) with a follow up of >1 year, appears to occur relatively frequently after liver transplantation (LTx). There is a pressing need to establish reliable biomarkers to monitor patients who may discontinue IS without risk of rejection. In addition, identification of biomarkers might provide insight into mechanisms of OT that could lead to development of novel therapies for induction of tolerance. Several potential clinical biomarkers have been identified, mainly by retrospective studies using either peripheral blood or graft biopsy tissues. These candidate biomarkers include regulatory T cells (Tregs), γδ T cells, natural killer (NK) cells, B cells, donor-specific antibody (DSA) and/or C4d deposition, dendritic cell (DC) subset ratio, serum human leukocyte antigen-G (HLA-G), and cytokine expression or polymorphism. In the next phase, further large-scale prospective studies are needed to validate existing candidate biomarkers of OT in LTx patients.

PROPE TOLERANCE: A MORE REALISTIC APPROACH TO IMPROVE LONG-TERM OUTCOMES FOR PEDIATRIC LIVING-DONOR LIVER TRANSPLANTATION: 2284

H. Ohe1, T. Koshiba2, Y. Li2, S. Sakaguchi2, K.J. Wood3, S.R. Calne4, S. Uemoto2 1Department Of Surgery, Kyoto University Grasuate School of Medicine, Kyoto/JAPAN, 2Hepatopancreatobillary Surgery And Liver Transplantation, Kyoto University Hospital, Kyoto/JAPAN, 3Transplantation Research Immunology Group, Nuffield Department of Surgery, University of Oxford, Oxford/UNITED KINGDOM, 4Surgery, University of Cambridge, CB2 2AS/UNITED KINGDOM